Back to News
Market Impact: 0.35
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
Source: zacks.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
VCYT beat Q3 earnings estimates but trimmed its 2026 revenue outlook. The company cited slower Decipher growth and increased investment in breast and bladder cancer testing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
VCYT-0.35
More News
- VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku